Faeth Therapeutics (FTH) Change in Accured Expenses (2020 - 2026)

Faeth Therapeutics (FTH) has 7 years of Change in Accured Expenses data on file, last reported at -$104000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 91.06% year-over-year to -$104000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 260.9% YoY) and the FY2025 annual result came in at $233000.0, down 65.02% from the prior year.
• Change in Accured Expenses fell to -$104000.0 in Q1 2026, from $959000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.6 million in Q1 2022 to a low of -$2.7 million in Q2 2022.
• A 5-year average of $127176.5 and a median of $242000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 4984.62% in 2022, down 2178.12% in 2022.
• Tracing FTH's Change in Accured Expenses over 5 years: stood at -$184000.0 in 2022, then plunged by 288.59% to -$715000.0 in 2023, then surged by 202.52% to $733000.0 in 2024, then jumped by 30.83% to $959000.0 in 2025, then tumbled by 110.84% to -$104000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$104000.0 (Q1 2026), $959000.0 (Q4 2025), and $381000.0 (Q3 2025), per Business Quant data.